Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials

被引:120
作者
Gibson, CM
Dumaine, RL
Gelfand, EV
Murphy, SA
Morrow, DA
Wiviott, SD
Giugliano, RP
Cannon, CP
Antman, EM
Braunwald, E
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, TIMI Study Grp,Cardiovasc Div, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
kidney disease; acute coronary syndromes; prognosis; TIMI risk score;
D O I
10.1016/j.ehj.2004.08.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To determine the association of glomerular filtration rate (GFR) with clinical outcomes in the setting of non-ST-segment elevation acute coronary syndromes (NSTE-ACS). Methods and results Data were pooled from five NSTE-ACS TIMI trials (TIMI 11 A and B, TIMI 12, OPUS-TIMI 16 and TACTICS-TIMI 18) and were available in 13 307 patients. GFR was assessed as a continuous and a categorical variable (normal: greater than or equal to 90 mL/ min/1.73 m(2), n = 4952; mildly decreased: 60-89 mL/min/1.73 m(2), n = 6262; and moderately to severely decreased GFR: < 60 mL/min/1.73 m(2), n = 2093). There was an independent association between decreasing GFR and mortality at 30 days (OR 1.19, 95% CI 1.12-1.27, p < 0.001) and at 6 months (OR 1.16, 95% CI 1.11-1.22, p < 0.001). The combination of TIMI risk score (TRS) and decreasing GFR provided further mortality risk stratification with highest 30-day and 6-month mortality rates among patients with the lowest GFR who also had a TRS greater than or equal to 5 (9.1% and 15.4%, respectively). Decreasing GFR was also independently associated with stroke and recurrent ischaemia at 30-days as well as with major bleeding (p < 0.001). Conclusion In the setting of NSTE-ACS, impaired GFR is associated with higher mortality as well as higher rates of thrombotic and major bleeding events, independent of TRS. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1998 / 2005
页数:8
相关论文
共 41 条
[1]   Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes [J].
Al Suwaidi, J ;
Reddan, DN ;
Williams, K ;
Pieper, KS ;
Harrington, RA ;
Califf, RM ;
Granger, CB ;
Ohman, EM ;
Holmes, DR .
CIRCULATION, 2002, 106 (08) :974-980
[2]  
[Anonymous], 1997, J Am Coll Cardiol, V29, P1474
[3]   The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making [J].
Antman, EM ;
Cohen, M ;
Bernink, PJLM ;
McCabe, CH ;
Horacek, T ;
Papuchis, G ;
Mautner, B ;
Corbalan, R ;
Radley, D ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (07) :835-842
[4]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[5]   Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CIRCULATION, 2002, 106 (23) :2941-2945
[6]   Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction [J].
Beattie, JN ;
Soman, SS ;
Sandberg, KR ;
Yee, J ;
Borzak, S ;
Garg, M ;
McCullough, PA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1191-1200
[7]   The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions [J].
Best, PJM ;
Lennon, R ;
Ting, HH ;
Bell, MR ;
Rihal, CS ;
Holmes, DR ;
Berger, PB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1113-1119
[8]  
Cannon CP, 1998, CIRCULATION, V97, P340
[9]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[10]   Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial [J].
Cannon, CP ;
McCabe, CH ;
Wilcox, RG ;
Langer, A ;
Caspi, A ;
Berink, P ;
Lopez-Sendon, J ;
Toman, J ;
Charlesworth, A ;
Anders, RJ ;
Alexander, JC ;
Skene, A ;
Braunwald, E .
CIRCULATION, 2000, 102 (02) :149-156